Cancer Biology Research — CFDA 93.396

Research obligations at $6.67 billion

USAspending.gov records $6,672,662,526.62 in obligations under CFDA 93.396. Three thousand four awards produce that stock. A simple average is about $2.22 million per award — typical of multi-year research grants rather than state block grants that post one large annual action. That average is a quotient of two packet totals, not a typical R01 budget line.

The assistance-listing title is CANCER BIOLOGY RESEARCH. CFDA 93.396 is the identifier. Other cancer-research listings, if tagged under other CFDA numbers, are not included in the $6.67 billion. Cause-and-prevention, treatment, and control rows live on their own codes if they appear in the file. Keep 93.396 separate when citing the obligation stock.

Hundreds of recipients, thousands of awards

Three hundred thirty-six recipients share 3,004 awards, or about 8.9 award records per recipient on average. Splitting $6.67 billion evenly would assign about $19.9 million per recipient. That pattern matches a research portfolio in which institutions hold multiple awards. The packet does not list the 336. Recipient count is the organizational headcount, not a census of principal investigators.

Forty-nine states in the geographic count show broad coding without covering every coded jurisdiction. Research dollars still concentrate at large biomedical campuses. The state count does not flatten those differences. Place-of-performance amounts are on the program table. A 49-jurisdiction code set is not a claim that every state received an equal share.

Award count is not a study count

Among research listings, 93.396 is a dense file: 3,004 rows against 336 recipients. Competing renewals, supplements, and related actions can inflate award count relative to unique projects. Award count is therefore a weak proxy for “number of cancer-biology studies.” Recipients (336) tell you how many named organizations sit on the extract; awards (3,004) tell you how many assistance rows were stored.

The packet does not report publication counts, trial enrollments, or disease outcomes. Citing 3,004 as papers or patients would be a unit error. A single award can fund many experiments; a single experiment can sit under other CFDA numbers. Keep the units straight: dollars, awards, recipients, states.

Obligations versus research outlays

The $6.67 billion is an obligation total from USAspending.gov. Outlays — cash paid against research awards — are not in the packet. A laboratory can show a large obligation stock while draws follow a multi-year grant calendar. Deobligations and upward adjustments both move the total. A remaining-balance question is an outlay question this extract does not answer.

Use CFDA 93.396 to size the Cancer Biology Research listing in the assistance file. Do not use it as a scientific-progress scorecard. Publications, patents, and clinical results live in other series. This page reports the obligation book tagged 93.396.

What the 93.396 tables omit

The Cancer Biology Research hub lists award-backed obligations from USAspending.gov. It is not a publication index, not a trial registry, and not a patient census. Series that never appear as assistance awards will not show up in the $6,672,662,526.62. That omission is definitional rather than a gap in the 3,004 award rows.

Place-of-performance on 49 states is a coding field. Read the program page before treating those cells as equal shares. Recipient dollars, if shown on the hub, are still obligation amounts, not cash already spent on reagents or staff.

Where the 93.396 table lives

The Cancer Biology Research program page overlays these four facts. The all-programs index ranks 93.396 among other assistance listings. Agency pages show awarding-agency rollups that may include this CFDA among other health-research listings. For 93.396 only, start on the program page. USAspending.gov assistance awards on SpendingVault are the source for this extract.

CFDA 93.396’s 3,004 awards spread $6,672,662,526.62 across 336 recipients and 49 states. Quote award count as a record count, recipient count as the organizational headcount, and dollars as obligations from USAspending.gov. About 8.9 award records per recipient is the density story on this research listing; 49 states complete the four-fact citation. Outlays remain a separate column and are not in this extract. Source: USAspending.gov assistance awards. The four-fact citation for CFDA 93.396 is the obligation stock on this extract, together with the award, recipient, and state counts already named above. Do not convert those figures into outlays, and do not treat award count as a service census.

Questions

How much is obligated for Cancer Biology Research?

USAspending.gov records $6,672,662,526.62 in obligations for CFDA 93.396. SpendingVault indexes 3,004 awards, 336 recipients, and 49 states. The figure is an obligation sum from assistance awards, not an outlay and not a count of studies. CFDA 93.396’s $6.67 billion is the USAspending obligation stock.

How many awards does CFDA 93.396 carry?

The listing shows 3,004 awards against 336 recipients, or about 8.9 award records per recipient. A simple average is about $2.22 million per award. Award count is not a publication or patient count. Recipient dollars are on the program page.

How many organizations receive Cancer Biology Research awards?

The extract lists 336 recipients. Those are organizational recipients on assistance awards tagged 93.396. Geographic coding covers 49 states. The packet does not name the 336 or publish scientific output. Recipient count is the organizational headcount, not a lab census.

Is $6.67 billion already spent on cancer biology?

Not necessarily. Obligations are commitments. Outlays are payments. CFDA 93.396’s indexed total is the obligation stock from USAspending.gov. This page does not report cash drawn, remaining balances, or research results. The $6.67 billion on 3,004 awards is the obligation figure.